about
TOM1 genes map to human chromosome 22q13.1 and mouse chromosome 8C1 and encode proteins similar to the endosomal proteins HGS and STAMRegulation of MYCN expression in human neuroblastoma cells.Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference.Early identification of antigen-specific immune responses in vivo by [18F]-labeled 3'-fluoro-3'-deoxy-thymidine ([18F]FLT) PET imaging.The role of interleukin-1 beta in the pathophysiology of Schnitzler's syndrome.Humoral and cellular immune responses after influenza vaccination in patients with postcancer fatigue.Long-lasting multifunctional CD8(+) T cell responses in end-stage melanoma patients can be induced by dendritic cell vaccination.Toll-like receptor signalling on Tregs: to suppress or not to suppress?Changes in peripheral immune cell numbers and functions in octogenarian walkers - an acute exercise study.Regulatory T cells in melanoma: the final hurdle towards effective immunotherapy?Antigen excess in modern immunoassays: to anticipate on the unexpected.Early predictive value of multifunctional skin-infiltrating lymphocytes in anticancer immunotherapy.Selective cancer-germline gene expression in pediatric brain tumorsSorafenib reduces the percentage of tumour infiltrating regulatory T cells in renal cell carcinoma patients.Monitoring of dynamic changes in Keyhole Limpet Hemocyanin (KLH)-specific B cells in KLH-vaccinated cancer patients.Quantitative measurement of immunoglobulins and free light chains using mass spectrometry.Dendritic Cells as Vaccines: Key Regulators of Tolerance and ImmunityIntranodal vaccination with mRNA-optimized dendritic cells in metastatic melanoma patientsMaturation of monocyte-derived dendritic cells with Toll-like receptor 3 and 7/8 ligands combined with prostaglandin E2 results in high interleukin-12 production and cell migration.Regulatory T cells and the PD-L1/PD-1 pathway mediate immune suppression in malignant human brain tumors.Recognition and management of common, rare, and novel serum protein electrophoresis and immunofixation interferences.Evaluation of a new free light chain ELISA assay: bringing coherence with electrophoretic methods.Prognostic significance and mechanism of Treg infiltration in human brain tumors.Anti-SSA antibodies are present in immunoglobulin preparations.Interference of daratumumab in monitoring multiple myeloma patients using serum immunofixation electrophoresis can be abrogated using the daratumumab IFE reflex assay (DIRA).Is accuracy of serum free light chain measurement achievable?Analytical validation of the Hevylite assays for M-protein quantification.Development of a Targeted Mass-Spectrometry Serum Assay To Quantify M-Protein in the Presence of Therapeutic Monoclonal Antibodies.Development of a rapid and quantitative lateral flow assay for the simultaneous measurement of serum κ and λ immunoglobulin free light chains (FLC): inception of a new near-patient FLC screening tool.Response to: Interference of daratumumab on the serum protein electrophoresis.Fast, robust and high-resolution glycosylation profiling of intact monoclonal IgG antibodies using nanoLC-chip-QTOF.Severe exacerbation of Crohn's disease during sunitinib treatment.The Role of FcRn in the Pharmacokinetics of Biologics in Patients With Multiple Myeloma.Cancer patients treated with sunitinib or sorafenib have sufficient antibody and cellular immune responses to warrant influenza vaccination.Vaccination with mRNA-Electroporated Dendritic Cells Induces Robust Tumor Antigen-Specific CD4+ and CD8+ T Cells Responses in Stage III and IV Melanoma PatientsPD-1 blockade augments Th1 and Th17 and suppresses Th2 responses in peripheral blood from patients with prostate and advanced melanoma cancerSimultaneous Presence of Non- and Highly Mutated Keyhole Limpet Hemocyanin (KLH)-Specific Plasmablasts Early after Primary KLH Immunization Suggests Cross-Reactive Memory B Cell ActivationSkin-Test Infiltrating Lymphocytes Early Predict Clinical Outcome of Dendritic Cell-Based Vaccination in Metastatic MelanomaRoute of Administration Modulates the Induction of Dendritic Cell Vaccine-Induced Antigen-Specific T Cells in Advanced Melanoma PatientsDendritic Cell Vaccination in Combination with Anti-CD25 Monoclonal Antibody Treatment: A Phase I/II Study in Metastatic Melanoma Patients
P50
Q22010020-8B059114-ED9D-4A81-B9BE-7FB422DB7E6AQ33483702-0D02DED2-CCCE-4B08-B3EB-F542C6D1D5C4Q34520323-9001FE22-6D23-4FF6-A94D-3C14B7FBF2DCQ35546673-E16B8FCC-D873-4A3F-9A74-C1636E32278CQ35879125-DFFB84FE-A4AE-4EFE-8CAA-ED175748904DQ35887247-4D4EF40B-FA3D-42B2-BCE5-E0CB5A3A7229Q36597497-B5BFF7D1-F2C5-42A6-8DA4-ADCDE36B4A7CQ37186819-B1843FE7-6BCB-407B-A662-A8E0763F7B53Q37661439-8310F919-0548-44AF-9319-D00954ABDE6FQ37973820-1E5FF593-26EA-4A27-9CF2-0A03E5B02316Q38280723-6469F044-4761-4E12-9532-487AC3A82887Q38365774-F57FEA8B-0E69-4D11-A8E1-57FA2CDFF9FBQ39609814-D9692A23-3F14-4271-B9B6-23EB9F4192C8Q39838078-F8AFAF0C-0685-4BC6-A4A2-05D40C0ED0DAQ40277992-CBFAF5D8-306F-41B9-8A5F-E30669F7F6DFQ40744233-3179BD59-76D0-401F-B511-5BB3A33780E4Q41949368-6991B31F-BB0A-4A6D-9FE3-57DB67951DC1Q41967129-F643C26A-55BD-4C87-8B37-2C9DA2C38F89Q41968893-EB96312B-F6E3-4CF3-8FFE-168D53729718Q42554303-29136C7F-2641-4E91-97FB-302182082F80Q47901879-2B3D5FAC-87C8-48D6-91F5-73AAAE10E184Q47996073-4E909193-995A-47B0-9151-69EBBB343A1AQ48170914-5836EDC6-A949-450F-97F0-5FB21DD81F29Q48253282-CDB13B5B-C1A8-4291-8CBE-861548AD15F7Q48876310-F52A17A9-3BDC-47D3-B293-7D19F0FFFF08Q48906189-E6CF4181-F39E-411B-A988-EC97CEDFEB5BQ49350915-4F1EE41A-E1FC-492C-88E8-CEBC7A2AFE48Q50102053-B04455B9-80A1-4B17-92B8-A80EC1BA6F90Q50597311-E1302C8C-2876-4337-B0F5-1264D438A3D7Q51279530-29F49177-CFAA-4142-B0BE-E4C57BC2C7B6Q51457632-5FCC4650-C271-4295-8BB4-877F167E6B04Q54409748-04666FAC-657B-403A-B7C6-5D81AD2A7EE5Q54505198-14051709-46EE-4110-A7B1-017273C74175Q54578340-E565D545-81D2-40D1-8C4B-5079813DDA10Q56637518-3E017261-47AA-48CE-8E14-975C1BCE4B9AQ56898302-39833AEC-F63A-455E-B9DE-92F212A15CBBQ56959032-73AAB0E7-F1A5-42EB-AE09-BF327C089B1AQ58619897-C3B2D6D3-74B1-4AC6-8C55-C8D0E0529B48Q58619922-B80DBDB8-D5D0-43BE-846A-2819753B0D4DQ58619940-2891477D-E3CE-4EFB-BE6D-B811D12EB802
P50
description
researcher
@en
name
Jacobs JF
@nl
Joannes F. M. Jacobs
@en
type
label
Jacobs JF
@nl
Joannes F. M. Jacobs
@en
altLabel
Hans Jacobs
@en
Jacobs JF
@en
prefLabel
Jacobs JF
@nl
Joannes F. M. Jacobs
@en
P108
P106
P31
P496
0000-0002-6208-6386